Strategies for development of combination vaccines

Pediatric Infectious Disease Journal

Volumn 20, Issue 11 SUPPL., 2001, Pages

  Yeh, S H ^a   Ward, J I ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Combination vaccines; Development; Evaluation; Selection

Indexed keywords

ADJUVANT; ANTIGEN; BUFFER; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; PRESERVATIVE; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE; TETANUS TOXOID; VACCINE;

ANTIBODY TITER; ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG INTERACTION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; SEROTYPE; VACCINATION;

ANTIGENS; CHILD; HUMANS; IMMUNIZATION SCHEDULE; LICENSURE; SAFETY; UNITED STATES; VACCINES, COMBINED;

EID: 0035158906     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200111001-00001     Document Type: Article

References (18)

1. Prevention Recommended childhood immunization schedule: United States 2001
2. Safety and immunogenicity of acellular diphtheria-tetanuspertussis and Haemophilus conjugate vaccines given in combination or at separate injection sites
3. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants
4. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis
5. Withdrawal of rotavirus vaccine recommendation
6. Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children. Implications for vaccine strategies
7. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants
8. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components
9. The preservation of poliomyelitis vaccine with stabilized merthiolate
10. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants
11. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines
12. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants
13. FDA perspective on regulatory issues in vaccine development
14. Methods for estimating serologic correlates of protection
15. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine
16. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants
17. Similarity/equivalence trials for combination vaccines